A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Active:	Yes
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT06952504
Trial Phases:	Phase III	Protocol IDs:	2870-033 (primary) NCI-2025-04722 2024-519331-42-00 ENGOT-en29 GOG-3119 jRCT2011250020 TroFuse-033 U1111-1315-0794
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06952504

Summary

Researchers are looking for new ways to treat people with proficient mismatch repair
(pMMR) endometrial cancer (EC) that is advanced or recurrent.

- EC is a type of cancer that starts in the tissues inside the uterus (womb)

- pMMR indicates that certain normal proteins are present in the cancer cells

- Advanced means the cancer has spread locally or to other parts of the body
(metastatic) and cannot be removed with surgery

- Recurrent means the cancer came back after surgery

Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study
medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific
targets on cancer cells and delivers treatment to destroy those cells.

The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live
longer and without the cancer getting worse compared to people who receive pembrolizumab
alone.

Objectives

All participants undergo an initial Induction Phase of six cycles, each cycle consisting
of pembrolizumab + carboplatin + paclitaxel or docetaxel. Each cycle is three weeks.
Participants whose cancer does not progress enter the Maintenance Treatment Phase and are
then randomly assigned to pembrolizumab + sac-TMT or pembrolizumab monotherapy.
Participants whose cancer does progress will have the possibility to enter the Subsequent
Treatment Phase and are then randomly assigned to pembrolizumab + sac-TMT or sac-TMT
monotherapy.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.